These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 7176218)

  • 1. In vitro metabolism of sulindac and sulindac sulfide: enzymatic formation of sulfoxide and sulfone.
    Kitamura S; Tatsumi K
    Jpn J Pharmacol; 1982 Oct; 32(5):833-8. PubMed ID: 7176218
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Metabolism in vitro of sulindac. Sulfoxide-reducing enzyme systems in guinea pig liver.
    Kitamura S; Tatsumi K; Yoshimura H
    J Pharmacobiodyn; 1980 Jun; 3(6):290-8. PubMed ID: 6775073
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Renal metabolism of sulindac: functional implications.
    Miller MJ; Bednar MM; McGiff JC
    J Pharmacol Exp Ther; 1984 Nov; 231(2):449-56. PubMed ID: 6436473
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Stereoselective sulfoxidation of sulindac sulfide by flavin-containing monooxygenases. Comparison of human liver and kidney microsomes and mammalian enzymes.
    Hamman MA; Haehner-Daniels BD; Wrighton SA; Rettie AE; Hall SD
    Biochem Pharmacol; 2000 Jul; 60(1):7-17. PubMed ID: 10807940
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sulfoxide reduction. In vitro reduction of sulindac by rat hepatic cytosolic enzymes.
    Ratnayake JH; Hanna PE; Anders MW; Duggan DE
    Drug Metab Dispos; 1981; 9(2):85-7. PubMed ID: 6113122
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of dimethyl sulfoxide on sulindac disposition in rats.
    Swanson BN; Mojaverian P; Boppana VK; Dudash MR
    Drug Metab Dispos; 1981; 9(6):499-502. PubMed ID: 6120805
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Thioredoxin-dependent sulfoxide reduction by rat renal cytosol.
    Anders MW; Ratnayake JH; Hanna PE; Fuchs JA
    Drug Metab Dispos; 1981; 9(4):307-10. PubMed ID: 6114827
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of sulindac metabolism by dimethyl sulfoxide in the rat.
    Swanson BN; Mojaverian P; Boppana VK
    J Toxicol Environ Health; 1983; 12(2-3):213-22. PubMed ID: 6655731
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of uremia and anephric state on the pharmacokinetics of sulindac and its metabolites in rats. I. An application of pharmacokinetic model for reversible metabolism.
    Lin JH; Yeh KC; Duggan DE
    Drug Metab Dispos; 1985; 13(5):602-7. PubMed ID: 2865111
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of the biologically active form of sulindac.
    Duggan DE; Hooke KF; Risley EA; Shen TY; Arman CG
    J Pharmacol Exp Ther; 1977 Apr; 201(1):8-13. PubMed ID: 850147
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Kinetics of the tissue distributions of sulindac and metabolites. Relevance to sites and rates of bioactivation.
    Duggan DE; Hooke KF; Hwang SS
    Drug Metab Dispos; 1980; 8(4):241-6. PubMed ID: 6105058
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reduction of Sulindac to its active metabolite, sulindac sulfide: assay and role of the methionine sulfoxide reductase system.
    Etienne F; Resnick L; Sagher D; Brot N; Weissbach H
    Biochem Biophys Res Commun; 2003 Dec; 312(4):1005-10. PubMed ID: 14651971
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative disposition of sulindac and metabolites in five species.
    Duggan DE; Hooke KF; Noll RM; Hucker HB; Van Arman CG
    Biochem Pharmacol; 1978; 27(19):2311-20. PubMed ID: 103551
    [No Abstract]   [Full Text] [Related]  

  • 14. Biotransformation of sulindac in end-stage renal disease.
    Gibson TP; Dobrinska MR; Lin JH; Entwistle LA; Davies RO
    Clin Pharmacol Ther; 1987 Jul; 42(1):82-8. PubMed ID: 3595070
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dimethyl sulfoxide inhibits bioactivation of sulindac.
    Swanson BN; Boppana VK; Vlasses PH; Rotmensch HH; Ferguson RK
    J Lab Clin Med; 1983 Jul; 102(1):95-101. PubMed ID: 6854139
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of uremia and anephric state on the pharmacokinetics of sulindac and its metabolites in rats. II. Differential effects on the biliary excretion.
    Lin JH; Yeh KC; Duggan DE
    Drug Metab Dispos; 1985; 13(5):608-13. PubMed ID: 2865112
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Studies on the chirality of sulfoxidation catalyzed by bacterial flavoenzyme cyclohexanone monooxygenase and hog liver flavin adenine dinucleotide containing monooxygenase.
    Light DR; Waxman DJ; Walsh C
    Biochemistry; 1982 May; 21(10):2490-8. PubMed ID: 7093199
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sulindac: therapeutic implications of the prodrug/pharmacophore equilibrium.
    Duggan DE
    Drug Metab Rev; 1981; 12(2):325-37. PubMed ID: 7040018
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sulphoxide reduction by rat and rabbit tissues in vitro.
    Lee SC; Renwick AG
    Biochem Pharmacol; 1995 May; 49(11):1557-65. PubMed ID: 7786296
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of the effects of sulindac with other cyclooxygenase inhibitors on prostaglandin excretion and renal function in normal and chronic bile duct-ligated dogs and swine.
    Zambraski EJ; Chremos AN; Dunn MJ
    J Pharmacol Exp Ther; 1984 Mar; 228(3):560-6. PubMed ID: 6423807
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.